top of page
EJP RD launched its second Joint Transnational Call (JTC2020) co-funded with the European Commission to fund multilateral “Pre-Clinical Research to Develop Effective Therapies for Rare Diseases”. The Project - TREATKCNQ : Targeted treatment for KCNQ related encephalopathies: retigabine analogues, repurposed drugs and allele specific knock down received the approval and founded.
EJP RD launched its second Joint Transnational Call (JTC2020) co-funded with the European Commission to fund multilateral “Pre-Clinical Research to Develop Effective Therapies for Rare Diseases”. The Project -SCN1A-up! : Therapeutic strategies for Dravet syndrome: upregulation of endogenous SCN1A and modulation of remodeling received the approval and founded.
bottom of page